Np mrd loader

Record Information
Version2.0
Created at2022-04-28 06:03:40 UTC
Updated at2022-04-28 06:03:40 UTC
NP-MRD IDNP0061172
Secondary Accession NumbersNone
Natural Product Identification
Common Name3'-Hydroxy-3,4,4'5-tetramethoxystilbene
DescriptionCombretastatin A4, also known as CA4DP or CRC 87-09, belongs to the class of organic compounds known as stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids. 3'-Hydroxy-3,4,4'5-tetramethoxystilbene is found in Combretum caffrum. 3'-Hydroxy-3,4,4'5-tetramethoxystilbene was first documented in 2021 (PMID: 34371485). Based on a literature review a significant number of articles have been published on Combretastatin A4 (PMID: 34342437) (PMID: 35139789) (PMID: 35104671) (PMID: 35026565) (PMID: 34970997) (PMID: 34959731).
Structure
Thumb
Synonyms
ValueSource
1-(3,4,5-Trimethoxyphenyl)-2-(3'-hydroxy-4'-methoxyphenyl)etheneMeSH
2-Methoxy-5-((Z)-2-(3,4,5-trimethoxyphenyl)vinyl)phenyl dihydrogen phosphateMeSH
3,4,5-Trimethoxy-3'-hydroxy-4'-methoxystilbeneMeSH
CA4dpMeSH
CRC 87-09MeSH
CRC-98-09MeSH
Combretastatin a-4MeSH
Combretastatin a-4 disodium phosphateMeSH
Combretastatin a4 phosphateMeSH
Deoxycombretastatin a-4MeSH
FosbretabulinMeSH
Isocombretastatin a-4MeSH
Phenol, 2-methoxy-5-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-,1-(dihydrogen phosphate)MeSH
Phenol, 2-methoxy-5-((Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, dihydrogen phosphateMeSH
Chemical FormulaC18H20O5
Average Mass316.3530 Da
Monoisotopic Mass316.13107 Da
IUPAC Name2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenol
Traditional Namecombretastatin A-4
CAS Registry NumberNot Available
SMILES
COC1=CC=C(\C=C/C2=CC(OC)=C(OC)C(OC)=C2)C=C1O
InChI Identifier
InChI=1S/C18H20O5/c1-20-15-8-7-12(9-14(15)19)5-6-13-10-16(21-2)18(23-4)17(11-13)22-3/h5-11,19H,1-4H3/b6-5-
InChI KeyHVXBOLULGPECHP-WAYWQWQTSA-N
Experimental Spectra
Not Available
Predicted Spectra
Spectrum TypeDescriptionDepositor IDDepositor OrganizationDepositorDeposition DateView
1D NMR13C NMR Spectrum (1D, 25 MHz, D2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 100 MHz, D2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 252 MHz, D2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 1000 MHz, D2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 50 MHz, D2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 200 MHz, D2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 75 MHz, D2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 300 MHz, D2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 101 MHz, D2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 400 MHz, D2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 126 MHz, D2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 500 MHz, D2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 151 MHz, D2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 600 MHz, D2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 176 MHz, D2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 700 MHz, D2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 201 MHz, D2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 800 MHz, D2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR13C NMR Spectrum (1D, 226 MHz, D2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
1D NMR1H NMR Spectrum (1D, 900 MHz, D2O, predicted)Wishart LabWishart LabDavid Wishart2021-06-20View Spectrum
Chemical Shift Submissions
Not Available
Species
Species of Origin
Species NameSourceReference
Combretum caffrumPlant
Chemical Taxonomy
Description Belongs to the class of organic compounds known as stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassStilbenes
Sub ClassNot Available
Direct ParentStilbenes
Alternative Parents
Substituents
  • Stilbene
  • Methoxyphenol
  • Phenoxy compound
  • Anisole
  • Methoxybenzene
  • Styrene
  • Phenol ether
  • 1-hydroxy-4-unsubstituted benzenoid
  • 1-hydroxy-2-unsubstituted benzenoid
  • Alkyl aryl ether
  • Phenol
  • Benzenoid
  • Monocyclic benzene moiety
  • Ether
  • Organooxygen compound
  • Hydrocarbon derivative
  • Organic oxygen compound
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Physical Properties
StateNot Available
Experimental Properties
PropertyValueReference
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water SolubilityNot AvailableNot Available
LogPNot AvailableNot Available
Predicted Properties
PropertyValueSource
logP3.32ALOGPS
logP3.38ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)9.84ChemAxon
pKa (Strongest Basic)-4.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area57.15 ŲChemAxon
Rotatable Bond Count6ChemAxon
Refractivity89.35 m³·mol⁻¹ChemAxon
Polarizability33.5 ųChemAxon
Number of Rings2ChemAxon
BioavailabilityYesChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
HMDB IDNot Available
DrugBank IDNot Available
Phenol Explorer Compound IDNot Available
FoodDB IDNot Available
KNApSAcK IDC00015429
Chemspider ID4508364
KEGG Compound IDC20268
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkCombretastatin A-4
METLIN IDNot Available
PubChem Compound5351344
PDB IDNot Available
ChEBI IDNot Available
Good Scents IDNot Available
References
General References
  1. Li YH, Lu JQ, Deng XW, Wang X, Jia F, Zhong SH, Cui XY, Pan ZA, Shao LH, Wu Y: Self-assembling Combretastatin A4 Incorporated Protamine/Nanodiamond Hybrids for Combined Anti-angiogenesis and Mild Photothermal Therapy in Liver Cancer. Nanotechnology. 2021 Aug 9. doi: 10.1088/1361-6528/ac1be0. [PubMed:34371485 ]
  2. Schmidt C, Babu T, Kostrhunova H, Timm A, Basu U, Ott I, Gandin V, Brabec V, Gibson D: Are Pt(IV) Prodrugs That Release Combretastatin A4 True Multi-action Prodrugs? J Med Chem. 2021 Aug 12;64(15):11364-11378. doi: 10.1021/acs.jmedchem.1c00706. Epub 2021 Aug 3. [PubMed:34342437 ]
  3. Cao Y, Ahmed AMQ, Du HH, Sun W, Lu X, Xu Z, Tao J, Cao QR: Combretastatin A4-loaded Poly (Lactic-co-glycolic Acid)/Soybean Lecithin Nanoparticles with Enhanced Drug Dissolution Rate and Antiproliferation Activity. Curr Drug Deliv. 2022 Aug 6;19(9):918-927. doi: 10.2174/1567201819666220209093443. [PubMed:35139789 ]
  4. Poojari R, Mohanty B, Kadwad V, Suryawanshi D, Chaudhari P, Khade B, Srivastava R, Gupta S, Panda D: Combinatorial cetuximab targeted polymeric nanocomplexes reduce PRC1 level and abrogate growth of metastatic hepatocellular carcinoma in vivo with efficient radionuclide uptake. Nanomedicine. 2022 Apr;41:102529. doi: 10.1016/j.nano.2022.102529. Epub 2022 Jan 30. [PubMed:35104671 ]
  5. Liu Y, Deng F, Zheng R, Chen X, Zhao L, Yu B, Chen A, Jiang X, Cheng H, Li S: Self-delivery nanomedicine for vascular disruption-supplemented chemo-photodynamic tumor therapy. J Colloid Interface Sci. 2022 Apr 15;612:562-571. doi: 10.1016/j.jcis.2021.12.128. Epub 2021 Dec 24. [PubMed:35026565 ]
  6. Rahman KMM, Thapa P, Hurst R, Woo S, You Y: Singlet Oxygen Activatable Prodrugs of Paclitaxel, SN-38, MMC and CA4: Nonmitochondria-Targeted Prodrugs. Photochem Photobiol. 2022 Mar;98(2):389-399. doi: 10.1111/php.13589. Epub 2022 Jan 11. [PubMed:34970997 ]
  7. Atanasov G, Rusew RI, Gelev VM, Chanev CD, Nikolova R, Shivachev BL, Petrov OI, Apostolova MD: New Heterocyclic Combretastatin A-4 Analogs: Synthesis and Biological Activity of Styryl-2(3H)-benzothiazolones. Pharmaceuticals (Basel). 2021 Dec 20;14(12):1331. doi: 10.3390/ph14121331. [PubMed:34959731 ]
  8. Mirzavi F, Barati M, Vakili-Ghartavol R, Roshan MK, Mashreghi M, Soukhtanloo M, Jaafari MR: Pegylated liposomal encapsulation improves the antitumor efficacy of combretastatin A4 in murine 4T1 triple-negative breast cancer model. Int J Pharm. 2022 Feb 5;613:121396. doi: 10.1016/j.ijpharm.2021.121396. Epub 2021 Dec 20. [PubMed:34942328 ]
  9. Paidakula S, Nerella S, Kankala S, Kankala RK: Recent Trends in Tubulin-Binding Combretastatin A-4 Analogs for Anticancer Drug Development. Curr Med Chem. 2022;29(21):3748-3773. doi: 10.2174/0929867328666211202101641. [PubMed:34856892 ]
  10. Zhong Y, Zhang L, Sun S, Zhou Z, Ma Y, Hong H, Yang D: Sequential drug delivery by injectable macroporous hydrogels for combined photodynamic-chemotherapy. J Nanobiotechnology. 2021 Oct 23;19(1):333. doi: 10.1186/s12951-021-01066-1. [PubMed:34688292 ]
  11. Yu X, Su Q, Chang X, Chen K, Yuan P, Liu T, Tian R, Bai Y, Zhang Y, Chen X: Multimodal obstruction of tumorigenic energy supply via bionic nanocarriers for effective tumor therapy. Biomaterials. 2021 Nov;278:121181. doi: 10.1016/j.biomaterials.2021.121181. Epub 2021 Oct 9. [PubMed:34653932 ]
  12. Zhang R, Cheng G, Liu S, Lv H, Li J: A four-in-one pure nanomedicine for synergistic multi-target therapy against breast cancer. J Mater Chem B. 2021 Nov 3;9(42):8809-8822. doi: 10.1039/d1tb01820e. [PubMed:34633023 ]
  13. Dai G, Zheng D, Liu G, Song Q: Synergistic Anticancer Effects of Cisplatin Combined with Combretastatin A4 Phosphate on Human Osteosarcoma-Xenografted Mice. Cells Tissues Organs. 2021;210(4):293-300. doi: 10.1159/000517446. Epub 2021 Aug 25. [PubMed:34433168 ]